Young A: Insulinotropic actions of ex-endin-4 and glucagon-like peptide-1 invivo and in vitro. Metabolism 50:583–589, 2001 16. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, BloomSR: Exendin-4 reduces fasting and post-prandial glucose and decreases energy in-take in healthy volunteers. Am J Physiol Endocrinol Metab 281:E155–E161, 2001 17. Nielsen LL, Young AA, Parkes D: Pharma- cology of exenatide (synthetic exendin-4): a potential therapeutic for improvedglycemic control of type 2 diabetes. Regul Pept117:77–88, 2004 18. Egan JM, Clocquet AR, Elahi D: The insu- linotropic effect of acute exendin-4 ad-ministered to humans: comparison ofnondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87:1282–1290, 2002 19. Holst JJ: Therapy of type 2 diabetes mel- litus based on the actions of glucagon-likepeptide-1. Diabetes Metab Res Rev 18: 430–441, 200220. Holst JJ, Gromada J: Role of incretin hor-